Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

Spectrum Health - Lakeland

Status and phase: Terminated; Phase 3

Conditions: Cyclic Vomiting Syndrome

Treatments: Drug: Droperidol; Drug: Haloperidol; Drug: Ondansetron 8mg

Study type: Interventional

Funder types: Other

Identifiers

NCT05065567

EGME#02-2021

Details and patient eligibility

About

The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.

Enrollment: 32 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adult patients with clinical diagnosis of cyclic vomiting in the ED

Exclusion criteria

• pregnancy, allergy to any of the study medicines

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

32 participants in 3 patient groups

haloperidol

Active Comparator group

Description:

these patients will receive 5mg IM haloperidol

Treatment:

Drug: Haloperidol

droperidol

Active Comparator group

Description:

these patients will receive 2.5mg IV droperidol

Treatment:

Drug: Droperidol

ondansetron

Active Comparator group

Description:

these patients will receive 8mg IV ondansetron

Treatment:

Drug: Ondansetron 8mg